NEW YORK, Dec. 6 (GenomeWeb News) - Definiens and BioImage will co-market their products for high-content cell-based screening assays, and co-develop applications in this area, the companies said today.
Under the non-exclusive deal, the companies will co-market Definiens' Cellenger software for automated image analysis and BioImage's Redistribution cell-based pathway screenings assays, which measure protein translocation.
In addition, Definiens, based in Munich, Germany, and BioImage of Copenhagen, Denmark, plan to co-develop specific applications for high-content screening.
